ClinicalTrials.gg
CompletedNCT07843446CHB-PATHUpdated Oct 13, 2026

Residual Histological Disease Across Treatment Pathways in Chronic Hepatitis B

An observational study in Chronic Hepatitis B, sponsored by Istanbul Medeniyet University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Istanbul Medeniyet University · Observational

How we know

Updated Sep 28, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,201
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Hepatitis B, Chronic with a site in Turkey — 1 open to participants now, 1 under way, none of them phase 3. Hepatitis B, Chronic · Turkey.

Started
2026
with 1 other
Observational
6 of 31
1 open now
Registered
31st of 31
by date
Lead sponsor
1 of 31
Istanbul Medeniyet University

Among the 31 studies in Hepatitis B, Chronic with a site in Turkey, this one is one of 2 that started in 2026, is one of 6 observational ones, and was the 31st registered.

Hepatitis B, Chronic

899 studies on the registry are indexed under Hepatitis B, Chronic; 154 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

1 of the 31 studies in Hepatitis B, Chronic with a site in Turkey is open now. Recruiting first, the newest first:

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Hepatitis B, Chronic with a site in Turkey, or all of them as a file.
02

Study summary

This retrospective, two-center observational study evaluates contemporary non-biopsy treatment pathways in treatment-naïve adults with chronic hepatitis B who underwent liver biopsy in routine clinical practice. The study retrospectively reconstructs the evaluable components of the WHO 2024, EASL 2025, APASL 2026, and Turkish Social Security Institution Health Implementation Communiqué (SUT) treatment pathways. The main objectives are to determine the proportion of patients classified as pathway-positive and to assess the frequency of clinically relevant histological disease among patients classified as pathway-negative. Histological disease is primarily defined as a histological activity index of at least 6 and/or Ishak fibrosis stage of at least 2. Analyses are performed overall and by study center, with additional sensitivity analyses using alternative histological definitions, a common biopsy period, and alternative alanine aminotransferase thresholds.

Read the detailed description

The study includes treatment-naïve adults with chronic hepatitis B who underwent pretreatment liver biopsy at two tertiary-care centers in Istanbul, Türkiye: Haydarpaşa Numune Training and Research Hospital and Göztepe Prof. Dr. Süleyman Yalçın City Hospital.

Clinical, virological, biochemical, hematological, and histological data were obtained retrospectively from institutional records and existing databases. Pretreatment laboratory measurements obtained within 3 months before liver biopsy are used. Histological activity is assessed using the histological activity index (HAI), and fibrosis is staged according to the Ishak system.

The primary histological outcome is significant histological disease, defined as HAI ≥6 and/or Ishak fibrosis stage ≥2.

Four contemporary non-biopsy treatment pathways are retrospectively reconstructed using the variables available in the harmonized datasets: the WHO 2024 pathway, the EASL 2025 biochemical pathway, the APASL 2026 biochemical pathway, and an exploratory Turkish SUT pathway.

These analyses do not represent complete implementation of all components of the respective guidelines because some clinical, liver-stiffness, longitudinal, fibrosis, and special-population criteria were not available in the retrospective datasets.

The principal analyses evaluate treatment-pathway positivity and the prevalence of significant histological disease among pathway-negative patients. Additional analyses assess histological disease among pathway-positive patients, individual inflammatory and fibrosis components, agreement between pathways, between-center differences, a stricter composite histological definition, fibrosis alone, restriction to the calendar period common to both centers, and alternative ALT thresholds.

03

Conditions studied

  • Chronic Hepatitis B

Keywords

  • Liver Biopsy
  • Liver Fibrosis
  • Histological Activity
  • Treatment Eligibility
  • Non-Biopsy Treatment Pathway
  • WHO 2024
  • EASL 2025
  • APASL
  • APRI
  • FIB-4
  • Turkish Social Security Institution
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with chronic hepatitis B who underwent liver biopsy as part of routine clinical management at two tertiary-care centers in Istanbul, Türkiye. Both cohorts were biopsy-referred clinical populations and therefore do not represent unselected population-based chronic hepatitis B cohorts.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years.
  • Documented surface antigen positivity for at least 6 months.
  • No oral antiviral therapy or interferon treatment before the index liver .
  • Evaluable pretreatment liver biopsy.
  • Availability of sufficient clinical and laboratory data for at least one relevant analysis.
  • If more than one pretreatment biopsy was available, only the first biopsy was included.

Exclusion criteria

Exclusion Criteria:

  • virus coinfection.
  • Hepatitis D virus coinfection.
  • coinfection.
  • Hepatocellular carcinoma.
  • Another chronic liver disease.
  • alcohol misuse.
  • Previous liver transplantation.
  • Inadequate histological assessment.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,201 participants (actual)
Patient registry
No

Groups and cohorts

  • Center A - Haydarpaşa Numune

    Treatment-naïve adults with chronic hepatitis B who underwent pretreatment liver biopsy at Haydarpaşa Numune Training and Research Hospital and met the study eligibility criteria.

  • Center B - Göztepe

    Treatment-naïve adults with chronic hepatitis B who underwent pretreatment liver biopsy at Göztepe Prof. Dr. Süleyman Yalçın City Hospital and met the study eligibility criteria.

06

What researchers measure

Primary outcomes

  1. Treatment-Pathway Positivity

    Proportion of evaluable participants classified as pathway-positive according to each of the four retrospectively reconstructed non-biopsy treatment pathways: WHO 2024, EASL 2025 biochemical pathway, APASL 2026 biochemical pathway, and exploratory Turkish SUT pathway.

    Time frame: At the index pretreatment assessment associated with liver biopsy; laboratory measurements obtained within 3 months before biopsy.

  2. Significant Histological Disease Among Pathway-Negative Participants

    Proportion of participants classified as pathway-negative who have significant histological disease, defined as histological activity index (HAI) ≥6 and/or Ishak fibrosis stage ≥2. The outcome is assessed separately for each treatment pathway and study center.

    Time frame: At the index pretreatment liver biopsy.

07

Study locations

1 site
  • Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi
    Istanbul, 34722, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2026 to primary completion in May 2026, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2026
First posted
Sep 28, 2026
StartActual
Jan 20, 2026
Primary completionActual
May 10, 2026
CompletionActual
Sep 1, 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 28, 2026
Show all 2 updates
  1. Oct 13, 2026
    Minor edits only
    + 1 other change: criteria formatting
  2. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07843446
Responsible party
Özgür Bahadır (Doctor, Istanbul Medeniyet University) — Principal investigator
First posted
Sep 28, 2026
Start date
Jan 20, 2026
Primary completion
May 10, 2026
Completion
Sep 1, 2026
Last update
Oct 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion